REG - Ovoca Bio PLC - Result of AGM

Ovoca BioAnnouncement

28/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221028:nRSb4106Ea&default-theme=true

RNS Number : 4106E  Ovoca Bio PLC  28 October 2022

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

 

Result of AGM

 

Dublin, Ireland, October 28, 2022 - Ovoca Bio, a biopharmaceutical company
with a focus on women's health, announces that all resolutions proposed at the
Company's Annual General Meeting held yesterday were passed. Voting on all
resolutions was conducted by poll and the results are available on the
Company's website at www.ovocabio.com (http://www.ovocabio.com/)  .

The full text of the approved resolutions can be found in the Notice of the
Annual General Meeting. The Notice is also available to view and download from
the Company's website.

 

End

 

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

 

 

 

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on
women's health. The Company is currently developing a novel treatment for
women with hypoactive sexual desire disorder (HSDD), a condition characterized
by a distressing lack or loss of sexual desire affecting an estimated ~4
million premenopausal women in the US alone.

 

The Company's lead product, Orenetide (BP-101), a novel synthetic peptide
administered through a nasal spray, is clinically validated, with Phase II and
Phase III studies conducted in Russia demonstrating statistically significant
improvement in a number of key efficacy outcomes, including an increase in
female sexual desire and reduction of symptoms of distress associated with
HSDD.

 

Ovoca Bio has been granted marketing approval in the Russian Federation and is
seeking to develop the drug for major global markets - in particular the
United States and Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBRBDGIBDDGDR